These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34046928)

  • 41. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
    Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
    Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
    Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield.
    Furundarena JR; Uranga A; Alkorta A; González C; Javier Ferreiro J; Rey M; Aragón L; Urreta I; Emparanza JI; Redín H; Garrido A; Araiz M
    Int J Lab Hematol; 2020 Apr; 42(2):170-179. PubMed ID: 31830371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation.
    Lane TA; Law P; Maruyama M; Young D; Burgess J; Mullen M; Mealiffe M; Terstappen LW; Hardwick A; Moubayed M
    Blood; 1995 Jan; 85(1):275-82. PubMed ID: 7528570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.
    Arora S; Majhail NS; Liu H
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):200-205. PubMed ID: 30679106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
    Teipel R; Rieprecht S; Trautmann-Grill K; Röllig C; Klötzer C; Zimmer K; Rathaj G; Bach E; Brückner M; Heyn S; Wang SY; Jentzsch M; Schwind S; Kretschmann T; Egger-Heidrich K; Remane Y; Franke GN; von Bonin M; Bornhäuser M; Platzbecker U; Hölig K; Merz M; Vučinić V
    Transfusion; 2023 Nov; 63(11):2131-2139. PubMed ID: 37850414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
    Bakeer M; Zubair AC; Roy V
    Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apheresis of Deceased Donors as a New Source of Mobilized Peripheral Blood Hematopoietic Stem Cells for Transplant Tolerance.
    Sosa RA; Mone T; Naini BV; Kohn DB; Reed EF; Wheeler K; Campo-Fernandez B; Davila A; Chaffin DJ; DiNorcia J; Kaldas FM; Cohen A; Lum EL; Veale JL; Kogut NM
    Transplantation; 2023 Feb; 107(2):504-510. PubMed ID: 35974436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
    Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
    Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C
    J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
    Zhuang L; Lauro D; Wang S; Yuan S
    J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of mobilization efficacy with an extended interval following plerixafor administration.
    Stump SE; Trepte M; Shaw JR; Grgic T; Ptachcinski JR; Sharf A; Riches M; Shea TC; Park YA; Alexander MD
    J Oncol Pharm Pract; 2020 Oct; 26(7):1590-1597. PubMed ID: 32063103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.